[go: up one dir, main page]

MX2010005095A - Moduladores novedosos de puntos de verificación del ciclo celular y su uso en combinacion con inhibidores de cinasa de puntos de verificacion. - Google Patents

Moduladores novedosos de puntos de verificación del ciclo celular y su uso en combinacion con inhibidores de cinasa de puntos de verificacion.

Info

Publication number
MX2010005095A
MX2010005095A MX2010005095A MX2010005095A MX2010005095A MX 2010005095 A MX2010005095 A MX 2010005095A MX 2010005095 A MX2010005095 A MX 2010005095A MX 2010005095 A MX2010005095 A MX 2010005095A MX 2010005095 A MX2010005095 A MX 2010005095A
Authority
MX
Mexico
Prior art keywords
cell cycle
combination
checkpoint kinase
kinase inhibitors
cycle checkpoints
Prior art date
Application number
MX2010005095A
Other languages
English (en)
Inventor
Kamil Paruch
Marc A Labroli
Timothy J Guzi
Janeta Popovici-Muller
Kristen E Rosner
David A Parry
Michael P Dwyer
Ruichao Shen
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40351703&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2010005095(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Schering Corp filed Critical Schering Corp
Publication of MX2010005095A publication Critical patent/MX2010005095A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • C07H19/067—Pyrimidine radicals with ribosyl as the saccharide radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • C07H19/073—Pyrimidine radicals with 2-deoxyribosyl as the saccharide radical

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)

Abstract

En sus muchas modalidades, la presente invención provee una clase novedosa de análogos de pirimidina de fórmula (V) como moduladores de mecanismo objetivo de los puntos de control del ciclo celular; los cánceres y/o enfermedades pueden tratarse por medio de la administración de un modulador de punto de control del ciclo celular de la invención; también se describen las combinaciones adecuadas del modulador de punto de control del ciclo celular con un inhibidor de cinasa de punto de control para producir apoptosis sinérgica en células cancerosas; la invención incluye métodos para tratar cáncer al administrar la combinación del modulador del punto de control del ciclo celular y el inhibidor de cinasas de punto de control, las composiciones farmacéuticas comprenden el activador así como la combinación y kits farmacéuticos.
MX2010005095A 2007-11-07 2008-11-05 Moduladores novedosos de puntos de verificación del ciclo celular y su uso en combinacion con inhibidores de cinasa de puntos de verificacion. MX2010005095A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US98608907P 2007-11-07 2007-11-07
PCT/US2008/082429 WO2009061781A1 (en) 2007-11-07 2008-11-05 Novel modulators of cell cycle checkpoints and their use in combination with checkpoint kinase inhibitors

Publications (1)

Publication Number Publication Date
MX2010005095A true MX2010005095A (es) 2010-08-03

Family

ID=40351703

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2010005095A MX2010005095A (es) 2007-11-07 2008-11-05 Moduladores novedosos de puntos de verificación del ciclo celular y su uso en combinacion con inhibidores de cinasa de puntos de verificacion.

Country Status (11)

Country Link
US (1) US8603998B2 (es)
EP (1) EP2217611B1 (es)
JP (1) JP2011503084A (es)
CN (1) CN101903396A (es)
AR (1) AR069198A1 (es)
CA (1) CA2705092A1 (es)
CL (1) CL2008003309A1 (es)
MX (1) MX2010005095A (es)
PE (1) PE20091195A1 (es)
TW (1) TW200927130A (es)
WO (1) WO2009061781A1 (es)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20091195A1 (es) 2007-11-07 2009-08-06 Schering Corp Nuevos moduladores de los puntos de control del ciclo celular y su uso en combinacion con inhibidores de quinasa de punto de control
AU2008343932B2 (en) 2007-12-19 2013-08-15 Amgen Inc. Fused pyridine, pyrimidine and triazine compounds as cell cycle inhibitors
JP5608097B2 (ja) 2008-01-08 2014-10-15 アレイ バイオファーマ、インコーポレイテッド キナーゼ阻害薬としてのピロロピリジン
CN101965347B (zh) 2008-01-09 2013-01-02 阵列生物制药公司 作为激酶抑制剂的吡唑并吡啶
ATE531372T1 (de) 2008-04-07 2011-11-15 Amgen Inc Gem-disubstituierte und spirocyclische aminopyridine/pyrimidine als zellcyclus- inhibitoren
CL2009001152A1 (es) 2008-05-13 2009-10-16 Array Biopharma Inc Compuestos derivados de n-(4-(cicloalquilo nitrogenado-1-il)-1h-pirrolo[2,3-b]piridin-3-il)amida, inhibidores de cinasa; proceso de preparacion; composicion farmaceutica; y su uso para el tratamiento de una enfermedad proliferativa.
KR20110128947A (ko) * 2009-03-20 2011-11-30 앨리오스 바이오파마 인크. 치환된 뉴클레오시드 및 뉴클레오티드 유사체
EP2473041B1 (en) * 2009-09-04 2018-03-07 Merck Sharp & Dohme Corp. Modulators of cell cycle checkpoints and their use in combination with checkpoint kinase inhibitors
US9227971B2 (en) * 2010-01-19 2016-01-05 Merck Sharp & Dohme Corp. Pyrazolo[1,5-a]pyrimidine compounds as mTOR inhibitors
WO2012129344A1 (en) 2011-03-23 2012-09-27 Amgen Inc. Fused tricyclic dual inhibitors of cdk 4/6 and flt3
WO2013009737A1 (en) 2011-07-13 2013-01-17 Merck Sharp & Dohme Corp. 5'-substituted nucleoside analogs and methods of use thereof for the treatment of viral diseases
WO2014062454A1 (en) * 2012-10-15 2014-04-24 Merck Sharp & Dohme Corp. Compositions and methods for treating cancer
CN104955458A (zh) * 2012-11-07 2015-09-30 Z·索 取代的吉西他滨芳基酰胺类似物和使用所述类似物的治疗方法
WO2015013579A1 (en) 2013-07-26 2015-01-29 Update Pharma Inc. Compositions to improve the therapeutic benefit of bisantrene
WO2016138026A1 (en) * 2015-02-25 2016-09-01 Ligand Pharmaceuticals, Inc. Gemcitabine derivatives
CN110234656B (zh) 2016-09-09 2023-02-28 卡利泰拉生物科技公司 外核苷酸酶抑制剂及其使用方法
MX383880B (es) 2016-12-22 2025-03-14 Antengene Therapeutics Ltd Inhibidores de ectonucleotidasa y metodos de uso de los mismos.
CA3061621A1 (en) * 2017-04-26 2018-11-01 Thomas I. Kalman Multitargeted nucleoside derivatives
US10435429B2 (en) 2017-10-03 2019-10-08 Nucorion Pharmaceuticals, Inc. 5-fluorouridine monophosphate cyclic triester compounds
AU2019207626B2 (en) 2018-01-10 2023-10-05 Nucorion Pharmaceuticals, Inc. Phosphor(n)amidatacetal and phosph(on)atalcetal compounds
US11427550B2 (en) 2018-01-19 2022-08-30 Nucorion Pharmaceuticals, Inc. 5-fluorouracil compounds
NZ771648A (en) 2018-06-21 2025-08-29 Antengene Therapeutics Ltd Ectonucleotidase inhibitors and methods of use thereof
CA3143349A1 (en) 2019-07-17 2021-01-21 Nucorion Pharmaceuticals, Inc. Cyclic deoxyribonucleotide compounds
AU2020402942B2 (en) * 2019-12-13 2023-05-11 Scinnohub Pharmaceutical Co., Ltd Fluorine-containing heterocyclic derivatives with macrocyclic structure and use thereof
CN115605492B (zh) 2020-04-21 2025-09-16 配体制药股份有限公司 核苷酸前药化合物
WO2024118503A1 (en) 2022-11-28 2024-06-06 Hongene Biotech Corporation Functionalized n-acetylgalactosamine analogs

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5168578A (ja) * 1974-12-10 1976-06-14 Mitsubishi Chem Ind Nukureoshidojudotaino seizoho
CA1264738A (en) 1984-12-04 1990-01-23 Eli Lilly And Company Treatment of tumors in mammals
US6749988B2 (en) 2000-11-29 2004-06-15 Shin-Etsu Chemical Co., Ltd. Amine compounds, resist compositions and patterning process
US7521557B2 (en) 2005-05-20 2009-04-21 Bristol-Myers Squibb Company Pyrrolopyridine-based inhibitors of dipeptidyl peptidase IV and methods
CN101321760A (zh) * 2005-10-06 2008-12-10 先灵公司 作为蛋白激酶抑制剂的吡唑并嘧啶
CN101360499B (zh) * 2005-10-06 2015-10-07 默沙东公司 吡唑并[1,5-a]嘧啶衍生物在制备抑制蛋白激酶的药物中的用途
BRPI0618520A2 (pt) * 2005-11-10 2011-09-06 Schering Corp imidazopirazinas como inibidores de proteìna cinase
CN101495481A (zh) * 2006-05-22 2009-07-29 先灵公司 作为CDK抑制剂的吡唑并[1,5-α]嘧啶
PE20091195A1 (es) 2007-11-07 2009-08-06 Schering Corp Nuevos moduladores de los puntos de control del ciclo celular y su uso en combinacion con inhibidores de quinasa de punto de control
EP2473041B1 (en) 2009-09-04 2018-03-07 Merck Sharp & Dohme Corp. Modulators of cell cycle checkpoints and their use in combination with checkpoint kinase inhibitors

Also Published As

Publication number Publication date
AR069198A1 (es) 2010-01-06
US8603998B2 (en) 2013-12-10
CL2008003309A1 (es) 2010-01-04
EP2217611A1 (en) 2010-08-18
US20110183933A1 (en) 2011-07-28
JP2011503084A (ja) 2011-01-27
PE20091195A1 (es) 2009-08-06
TW200927130A (en) 2009-07-01
WO2009061781A1 (en) 2009-05-14
EP2217611B1 (en) 2013-07-31
CA2705092A1 (en) 2009-05-14
CN101903396A (zh) 2010-12-01

Similar Documents

Publication Publication Date Title
MX2010005095A (es) Moduladores novedosos de puntos de verificación del ciclo celular y su uso en combinacion con inhibidores de cinasa de puntos de verificacion.
MX384721B (es) Tratamiento del cáncer usando combinaciones de inhibidores de erk y raf.
MX2013008212A (es) Derivados de 7-azaindol.
CL2010001475A1 (es) Compuestos derivados de ester boronato, inhibidores de proteasoma; composiciones farmaceuticas que los contienen; procedimiento de preparacion de la composición farmaceutica; utiles en el tratamiento de enfermedades proliferativas celulares, en particular cancer.
BRPI0919447B8 (pt) compostos derivados de ácido 1-amino-2- ciclobutiletilborônico, composição farmacêutica e uso dos mesmos para tratar câncer
EP4512480A3 (en) Cancer treatments using combinations of cdk and erk inhibitors
PE20090156A1 (es) Nuevas pirazolopirimidinas como inhibidores de quinasas dependientes de ciclinas
CL2008001633A1 (es) Compuestos derivados de pirrolidin-3-carboxamida; composición farmacéutica; y uso comominhibidores de erk para el tratamiento del cancer.
BR112013002079A2 (pt) modificadores do receptor de aril hidrocarboneto (ahr) como novos terapêuticos contra o câncer
GT200500237A (es) Derivados de pirimidina
BR112012022513A2 (pt) derivados de piperidin-4-il azetidina como inibidores de jak1
MY162514A (en) Combination therapy with nanoparticle compositions of taxane and hedgehog inhibitors
MX2009009117A (es) Derivados de pirimidin-2,4-diamina y su uso como inhibidores de la cinasa jak2.
PH12014501639B1 (en) Pharmaceutical compositions and methods
PL1660507T5 (pl) Inhibitory proteazomu oraz sposoby ich stosowania
MX336381B (es) Boronatos como inhibidores de arginasa.
MX2012004210A (es) Derivados de pirazol como moduladores del canal de calcio activado por liberacion de calcio.
ATE456571T1 (de) Proteasom-hemmer und verwendungsverfahren dafür
IN2012DN01964A (es)
EA201100125A1 (ru) Производные пирролопиридинилпиримидин-2-иламина
ECSP109953A (es) Derivados de piridazinona
EA201101585A1 (ru) 3-(1,2,3-триазол-4-ил)пирроло[2,3-b]пиридинпроизводные
SG170041A1 (en) Methods for cancer therapy and stem cell modulation
MX2014003376A (es) Derivados de acido benzoico como inhibidores eif4e.
CL2008002185A1 (es) Compuestos derivados de pirimidina, inhibidores de fosfatidilinositol-3-cinasa; composicion farmaceutica que comprende a dichos compuestos; y su uso para el tratamiento de enfermedades resapiratorias, alergias, inflamacion, cancer, entre otras enfermedades.

Legal Events

Date Code Title Description
FA Abandonment or withdrawal